Zydus Lifesci.
Drug Manufacturers - Specialty & Generic · ZYDUSLIFE
Large CapHealthcareHigh Growth
Dr. Sharvil Patel
Managing Director · Visionary
Company DNA
Innovation-Led
About
Zydus Lifesci. is a Large Cap company in the Healthcare sector, listed on NSE as ZYDUSLIFE. With a market cap of ₹91K Cr and revenue of ₹23K Cr, it is currently in the High Growth phase. Known for its Innovation-Led culture and Fast-Follower approach to innovation, the company operates at a Steady-Marathon pace. Heavy investment in R&D and focus on complex generics signifies a culture built around scientific product innovation. Its strategic mandate: Transitioning from generic manufacturing to complex specialty generics and novel drug discovery requires a leader focused on R&D-led growth.
FAQ
What kind of company is Zydus Lifesci.?
Zydus Lifesci. is a Large Cap Healthcare company (ZYDUSLIFE) in the High Growth phase with a market cap of ₹91K Cr. It is classified as Innovation-Led in culture.
What is Zydus Lifesci.'s culture and work environment like?
Zydus Lifesci. has a Innovation-Led culture with Fast-Follower innovation DNA and a Steady-Marathon pace of execution. Employee brand: Learning Ground. Customer relationship style: B2B-Enterprise. Heavy investment in R&D and focus on complex generics signifies a culture built around scientific product innovation.
Who leads Zydus Lifesci.?
Zydus Lifesci. is led by Dr. Sharvil Patel (Managing Director), a Visionary leader with 21 years of experience.
What are Zydus Lifesci.'s financials?
Zydus Lifesci. reported revenue of ₹23K Cr in FY25 with a 5-year revenue CAGR of 15%. Operating margin: 26.5%. Market cap: ₹91K Cr.
Culture & Strategy
CultureInnovation-Led
InnovationFast-Follower
PaceSteady-Marathon
PurposePurpose-Blended
CustomerB2B-Enterprise
EmployeeLearning Ground
BrandTrusted
LifecycleHigh Growth
Heavy investment in R&D and focus on complex generics signifies a culture built around scientific product innovation.
Mandate
Transitioning from generic manufacturing to complex specialty generics and novel drug discovery requires a leader focused on R&D-led growth.
Transitioning from generic manufacturing to complex specialty generics and novel drug discovery requires a leader focused on R&D-led growth.
Financials
Revenue FY25₹23K Cr
PAT FY25₹5K Cr
Rev CAGR 5Y15%
OPM26.5%
NPM20%
ROE18.9%
ROCE21.2%
P/E18.5
Fwd P/E21.8
P/B3.6
D/E34.3
Mkt Cap₹91K Cr
Promoter75.2%
Institutional14.9%
Similar Culture
Could You Lead Zydus Lifesci.?
Take the Genome Benchmark →